Why the study?
Do contemporary drug-eluting stents (Orsiro SES, Synergy EES, and Resolute Integrity ZES) have similar 5-year safety and efficacy outcomes in all-comers?
Do contemporary drug-eluting stents (Orsiro SES, Synergy EES, and Resolute Integrity ZES) have similar 5-year safety and efficacy outcomes in all-comers?
At 5 years, three contemporary drug-eluting stents (Orsiro SES, Synergy EES, and Resolute Integrity ZES) demonstrated similar safety and efficacy in an all-comer population, including those with diabetes.
Answers are grounded in this paper and cite their sources.
Allows flexibility in DES selection for all-comers; confirms long-term equivalence among contemporary platforms.
=0.63]). Conclusions Orsiro SES, Synergy EES, and Resolute Integrity ZES showed similar 5-year outcomes of safety and efficacy, including mortality. A prespecified stent comparison in patients with diabetes also revealed no significant differences in 5-year clinical outcomes. Registration URL: https://www.clinicaltrials.gov; Unique identifier: NCT01674803.
No takes yet. Share an insight, caveat, or question.
Ploumen et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: